Drugs / CIMAvax-EGF
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT06011772 | Dec 2023 → Feb 2026 overdue | colorectal cancer | Roswell Park Cancer Institute | Active not recruiting | No outcome recorded |
| Phase 0 | NCT04298606 | Nov 2021 → Dec 2025 | chronic obstructive pulmonary disease, non-small cell lung carcinoma, pneumonia | Roswell Park Cancer Institute | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CIMAvax-EGF | “This early phase I trial studies the side effects of a vaccine called CIMAvax-EGF and to see how well it works in preventing lung cancer from developing in patients at high...” NCT04298606 ↗1“EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer” NCT06011772 ↗ |
| Action | Inhibit | “CIMAvax-EGF vaccine works by causing the body to make antibodies against EGF” NCT04298606 ↗ |
| Modality | Vaccine | “CIMAvax-EGF vaccine” NCT04298606 ↗ |